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Abstract
Background:  Increased ST6Gal I activity has been associated with the α(2,6)sialylation
enhancement of membrane glycoconjugates observed in metastatic colorectal carcinomas (CRC).
Siaα(2,6)Galβ(1,4)GlcNAc sequence, known as CDw75, is a sialylated carbohydrate determinant
generated by the ST6Gal I. This epitope has been reported to be associated with the progression
of gastric and colorectal tumours, hence there are only a few conclusive studies to date.
Methods: By radioisotopic techniques we evaluated the ST6Gal I activity in healthy, transitional
and tumour tissues from 43 patients with CRC. By immunohistochemistry we assessed the CDw75
expression in 25 colorectal adenomas, 43 tumours, 13 transitional and 28 healthy tissues of CRC
patients.
Results: ST6Gal I activity was likewise found to be statistically higher in tumour tissue respect to
healthy tissue from CRC patients. CDw75 expression was positive in 20% of colorectal adenomas.
Furthermore, 70% of tumour specimens and 8.3% of transitional specimens were positive for
CDw75 expression, whereas none of the healthy ones showed the presence of the epitope.
Conclusion: The major contribution of this study is the inclusion of data from transitional tissue
and the analysis of CDw75 antigen expression in CRC and in colorectal adenomas, little known so
far. ST6Gal I activity and CDw75 antigen expression were increased in CRC. Although their
comparison did not reach the statistical significance, a great extent of patients showed both, an
enhanced tumour ST6Gal I activity and an increased CDw75 expression in the tumour tissue. So,
these two variables may play a role in malignant transformation. The expression of CDw75 in
colorectal adenomas suggests that this antigen may be a tumour marker in CRC.
Background
The main role of oligosaccharide structures in recognition
phenomena is quite well known [1]. Thus, the oligosac-
charide antennae with terminal sialic acids, have been
related with the adhesive and invasive properties of cancer
cells [2]. Sialic acid is commonly found in glycoconju-
gates as α(2,3)- or α(2,6)-residues linked to galactose
(Gal), as α(2,6)-residues linked to N-acetylgalactosamine
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(GalNAc) or as α(2,8)-residues linked to other sialic acid
unit. Biosynthesis of these various linkages is catalyzed by
different members of the sialyltransferase family and it
depends on the exogenous substrate acceptor. In this
sense, the ST6Gal I [β-galactoside α(2,6)-sialyltransferase;
EC 2.4.99.1] catalyzes the formation of α(2,6) linkages;
however, it specifically targets terminal Galβ(1,4)GlcNAc
(N-acetyllactosamine) structures from glycoproteins.
There is yet another α(2,6) specific sialyltransferase iden-
tified, namely ST6Gal II, but this enzyme seems to prefer
oligosaccharides to glycoproteins as acceptor substrates
[3].
There is evidence that the ST6Gal I enzyme activity is sig-
nificantly higher than the ST6Gal II one in colorectal can-
cers (CRC) [4], and that one of their most significant
glycosylation changes is the elevation of ST6Gal I activity
in tumour tissues, when compared with the surrounding
healthy mucosa [5]. Additionally, several clinical studies
over the past few years, have shown that the ST6Gal I
activity is further increased by metastases [6] and that this
increase is associated with poor prognosis of the patients
[7]. Moreover, while increasing levels of the enzyme in
CRC are well established (it occurs in almost all samples
analyzed), some studies have also reported the ST6Gal I
mRNA increase, where it exclusively affected a handful of
cases [8-10].
In vitro cell culture studies have shown that ST6Gal I is up-
regulated by oncogenes such as ras  [11-14] and that
increased enzyme expression drives the enhancement of
β1-integrins adhesion receptor α(2,6)-sialylation [13].
Furthermore, Seales et al. [15] reported that β1-integrins
from colon adenocarcinomas showed increased α(2,6)-
sialylation in comparison with integrins from pair-
matched healthy epithelial tissues, suggesting that this
hypersialylation is correlated with tumour progression.
The enzyme ST6Gal I, synthesizes the
Siaα(2,6)Galβ(1,4)GlcNAc sequence, known as CDw75
antigen, a surface molecule in B lymphocytes. Despite
there being several studies focused on B lymphocyte
CDw75 expression, little is known to date about the
CDw75 expression in solid tumours. Nevertheless, several
studies conducted on gastric cancer, in which the authors
found the role of CDw75 as a marker of malignant trans-
formation, may be taken into account. These reports doc-
umented an increase of CDw75 expression in primary
tumours and metastatic gastric carcinomas [16-18], as
well as a worsening of patient's prognosis [17,18];
remarkably, none of the healthy mucosa showed CDw75
expression. In the case of the CRC, we understand that
only Elpek et al. [19] have developed a clinicopathologic
evaluation of CDw75 expression in tumour tissues where
healthy mucosa showed moderate and no expression,
respectively. However, there are no conclusive results to
date for ST6Gal I activity and CDw75 expression from
CRC. There are a few studies focused on ST6Gal I activity
in CRC and even fewer ones specifically concentrated on
healthy, transitional and tumour mucosa from the same
patient. Similarly, little is known of the role of CDw75 in
CRC as a tumour marker, and its behaviour in premalig-
nant lesions like adenomas hasn't been elucidated yet.
Consequently this pioneering work has been undertaken
to elucidate the response of CRC α(2,6)-sialylation as
malignancy progresses, by evaluating both, the ST6Gal I
enzyme activity and the CDw75 tissue expression in color-
ectal adenomas and in healthy, transitional and tumour
CRC specimens from the same patients.
Methods
Samples
A total of 43 patients (71.19 ± 1.51 years old) with color-
ectal adenocarcinoma and 25 patients (64.8 ± 2.76) with
colorectal adenomas, were randomly selected. They had
been diagnosed and treated at the University Hospital
Complex (CHOU, Ourense, Spain) between 1997 and
2006. Clinical information about the patients and clinico-
pathological parameters of the specimens were obtained
by the hospital medical charts and were treated in a confi-
dential and anonymous manner. The study has the posi-
tive evaluation of the "Comité Ético de Investigación
Clínica de Galiza" (Spain). All procedures involving
human samples were performed according to the clinical
practices of the "Xunta de Galiza" and followed the tenets
of the Helsinki Declaration. All patients involved in the
study gave their informed consent to participate.
Colorectal adenomas were obtained by surgical polypec-
tomy. In addition, specimens of healthy (distant at least
10 cm away from tumour), transitional (immediately
adjacent to tumour but without microscopic features of
malignancy) and tumour tissues, from the same patient,
were acquired by surgical intervention. All specimens
were fixed in formaldehyde (10% v/v) and embedded in
paraffin for immunohistochemistry analysis. Aliquots
from the same CRC specimens were separated and frozen
at the time of surgery, and stored at -80°C until sialyl-
transferase activity determinations were carried out.
The fraction of total cell membranes from CRC speci-
mens, used as enzyme source, was obtained according to
the process described by López et al. [20]. The protein con-
centration of the final membrane fraction was determined
by the bicinchoninic acid protein assay (Sigma, St. Louis,
MO, USA) [21], using BSA (Sigma, St. Louis, MO, USA) as
standard.BMC Cancer 2009, 9:431 http://www.biomedcentral.com/1471-2407/9/431
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Sialyltransferase assays
ST6Gal I activity was determined using asialotransferrin
(AST) as exogenous acceptor. Transferrin (Sigma, St.
Louis, MO, USA) was desialylated by mild acid hydrolysis
(0.1 N H2SO4, 1 h, 80°C), according to the TBA method
for checking the process [22].
The sialyltransferase assay was carried out according to
Vázquez-Martín et al. [23]. The reaction mixture, in a total
volume of 100 μL, contained: NaF 4 mM, MnCl2 5 mM,
Triton X-100 0.2% (v/v), MES buffer 40 mM (pH 6), 50 μg
enzyme solution, 0.9 mg AST and 200 μM CMP-NeuAc [1
μM CMP-14C-NeuAc (specific activity 9.2-12 GBq/mmol,
77.4-80.32  μM, Amersham Biosciences, Uppsala, Swe-
den) and 199 μM CMP-NeuAc (Sigma, St. Louis, MO,
USA)] as donor substrate. The sialylated proteins from the
reaction were collected on Whatman glass filters. Radioac-
tivity was measured in a Wallac 1409-12 Scintillator sys-
tem using Ecoscint H (National Diagnostics, Atlanta, GA,
USA) as scintillation cocktail. Endogenous acceptor assays
were carried out by incubating standard cocktail reaction
without the exogenous acceptor (AST). Enzyme activity
was expressed as μU/mg of protein (U, international unit
of enzyme activity; quantity of enzyme that catalyzes the
conversion of 1 μmol of substrate per minute).
Immunohistochemical analysis
The immunohistochemical staining was performed with a
monoclonal mouse antibody against human CDw75
epitope (Clone LN-1, NeoMarkers, Fremont, CA, USA).
Sections (2-3 μm) of selected paraffin embedded tissue
blocks from healthy, transitional and tumour specimens
of CRC patients and colorectal adenomas, were deparaffi-
nized in xylene, rehydrated in a graded ethanol series, and
heated in a microwave oven for 15 min (with citrate buffer
10 M, pH 6.0) to retrieve antigens. Endogenous peroxi-
dase activity was blocked with a blocking solution (Perox-
idase block, EnVision™ Detection System, Dako,
Carpinteria, CA, USA) for 15 min. To avoid non-specific
unions, the tissue slides were exposed for 20 min in BSA.
The sections were then incubated with the primary anti-
body for 30 min (dilution 1/25) in a moist chamber. After
a rinse with PSB, the incubation with the secondary anti-
body bound to peroxidase (goat anti-mouse, labelled pol-
ymer, HRP, EnVision™ Detection System, Dako,
Carpinteria, CA, USA) was carried out for 30 min in a
moist chamber. The immunostaining was visualized with
3,3'-diaminobenzidine reagent. Finally, the sections were
counterstained with haematoxylin, dehydrated through
graded ethanol series and xylene, and mounted. Negative
controls were performed by substituting the primary anti-
body with PBS.
The evaluation of the immunohistochemical staining,
detected as a brown colour precipitate, was carried out
independently by two expert pathologists (CHOU), who
reached a final result by consensus. The staining pattern
was classified semi-quantitatively as follows: 0, tissues
without staining; 1, less than 10%; 2, 10-50%; and 3,
more than 50% of the tissue stained.
Statistical Analysis
The statistical analysis was carried out using the SPSS pro-
gram (14.0 version). Univariate analysis for categorical
data was conducted by means of the χ2 test or the Fisher's
exact probability test. For continuous data, we employed
the Wilcoxon's test, the Mann-Whitney U test and the
Kruskall-Wallis' test. Moreover, we performed a posteriori
test, the Dun test, when marginally significant p values
obtained suggested the existence of significant differences
between groups. Finally, the association between ST6Gal
I activity and CDw75 expression from the same specimen
was tested using the Spearman's correlation coefficient
test. The results were considered significant when p < 0.05.
Results
α(2,6)Sialyltransferase activity
Specimens of healthy, transitional and tumour tissues
from 43 CRC patients were processed and sialyltransferase
activity was determined in the total cell membrane frac-
tions. The experimental conditions specifically measured
the incorporation of NeuAc into AST, despising the incor-
poration onto endogenous acceptors. The incorporation
of NeuAc into endogenous acceptors was performed by
carrying out 8 independent assays without adding exoge-
nous acceptors, and employing specimens from 8 differ-
ent CRC patients. Levels of activity obtained were 4.37 ±
1.68 and 5.14 ± 1.77 μU/mg protein for healthy and
tumour specimens, respectively. There were no statisti-
cally significant differences between tumour and healthy
tissues (p = 0.91, according to Wilcoxon's test, data not
shown), therefore these were discarded in later assays.
Figure 1 shows α(2,6)ST6Gal activity measured in
healthy, transitional and tumour colorectal tissue speci-
mens from the same patient, using AST as exogenous
acceptor and an isotopic mixture CMP-14C-NeuAc/CMP-
NeuAc as donor substrate. Results showed that ST6Gal I
activity in tumour tissue samples was significantly higher
than in healthy ones (p = 0.003, Wilcoxon's test). The
transitional tissue activity was intermediate between
healthy control and tumour ones and showed no statisti-
cally significant differences.
On the other hand, α(2,6)ST6Gal specific activity in tis-
sues from the 43 CRC patients studied was examined to
find correlation with several standard clinicopathologic
features. This initial statistical analysis revealed no signif-
icant differences with age, tumour location, size, histolog-
ical grade or growth type (growth type according to Mann-BMC Cancer 2009, 9:431 http://www.biomedcentral.com/1471-2407/9/431
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Whitney U test, and the rest according to Kruskall-Wallis'
test; data not shown for healthy and transitional tissues,
first column of Table 1 for tumour tissue). Nevertheless, as
a new strategy to look for statistical differences of tumour
ST6Gal I activity, we considered the Tumour/Healthy
activities ratio and the Net increase of specific activity in a
tumour specimen with respect to the healthy one from the
same patient, and performed their corresponding evalua-
tion to find correlations (second and third columns of
Table 1, respectively). This new correlation study with the
standard clinicopathological features revealed a minor net
increase for >77-year-old patients, and a greater ratio
tumour/healthy for minor size tumours (Table 1). The
remainder of the variables did not reach statistically sig-
nificant differences (from Kruskall-Wallis' test), but sev-
eral marginally significant p  values were obtained
suggesting the presence of significant differences between
groups. A new statistical study was then conducted by
means of the Dun test (Table 2), a post-test which per-
forms multiple comparisons between variable groups.
The Dun test showed that differences found regarding the
age of the patients were mainly due to the increase of
ST6Gal I activity in patients that were < 69 years and > 77
years. So, there is a minor enhancement of activity as
patient's age increases. Furthermore, there was an inverse
relationship between activity levels and tumour size.
Finally, the Dun test revealed a statistically significant dif-
ference between moderately and well differentiated
tumour histological type, where the former showed
higher levels of ST6Gal I activity, of tumour/healthy activ-
ity ratio and net increase of activity in tumour specimens
(Table 2).
Tumour stage is one of the most important clinicopatho-
logic features and therefore the TNM and AJCC classifica-
tions were used, to test the correlation between the
tumour stage and both, the tumour/healthy ratio and the
net increase of ST6Gal I activity in the tumour tissue of
each patient (Table 1). Although the Kruskall-Wallis' test
did not reveal statistically significant differences between
tumour stage and ST6Gal I activity, a diminished activity
was noted in both the TNM and AJCC advanced tumour
stages. In this sense, the analysis of the data by means of
the Dun test, confirmed that there is a significant decrease
in tumour enzyme activity enhancement as the extent of
tumour infiltration progresses (Table 2).
Immunohistochemical expression of CDw75 antigen
The CDw75 expression was analyzed in colorectal adeno-
mas and in healthy, transitional and tumour specimens
from the same CRC patient. The immunohistochemical
analysis showed that the CDw75 antigen was detected in
20% of adenomas (n = 25) (Fig. 2). The degree of staining
in adenomas was as follows: 12% showed low expression
and 8% moderate expression. Likewise, all healthy tissues
(n = 28) were negative for immunohistochemical CDw75
staining (Fig. 2), while positive staining was detected in
67.9% of the tumour ones (n = 28) (Fig. 2), and 8.3% of
the transitional mucosa (n = 13). Accordingly, when the
total of tumour specimens available was considered (n =
43), more than 70% of tumour tissues showed positive
expression for the CDw75 antigen. The staining intensity
was as follows: 9.94% strong, 43.43% moderate and
46.63% low expression. Positive staining of CDw75 was
located as a brown precipitate in the cell cytoplasm; stain-
ing was diffuse in most cases (Fig. 3). The statistical anal-
ysis showed significant differences in CDw75 antigen
expression between healthy and tumour tissue (p = 0.046,
Wilcoxon's test), and between adenomas and tumour
specimens (p < 0.001, Mann-Whitney U test).
The  χ2 test was performed to study the expression of
CDw75 antigen in colorectal adenomas and tumours in
relation with the clinicopathological features. Results did
not demonstrate association between the expression of
the CDw75 antigen neither in adenomas nor in CRC and
the different clinicopathological parameters considered.
Likewise, the degree of expression of the CDw75 antigen
as well as the presence or absence of expression, did not
seem to correlate, with any of the considered variables
(data not shown).
TNM and AJCC classifications were used to correlate
CDw75 expression (presence or absence and degree of
expression) and the tumour stage, and the χ2 test was used
to perform the statistical analysis. Although there were no
significant differences, highest percentages of CDw75 pos-
ST6Gal I activity in healthy, transitional and tumour tissues  from the patients with CRC analyzed Figure 1
ST6Gal I activity in healthy, transitional and tumour 
tissues from the patients with CRC analyzed. Data are 
expressed as μU/mg protein and represent the means ± 
standard error of the means of the n independent determina-
tions carried out per duplicate. *p < 0.05 between tumour 
and its relative healthy tissue according to the Wilcoxon's 
test.BMC Cancer 2009, 9:431 http://www.biomedcentral.com/1471-2407/9/431
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itive expression in advanced tumour stages were observed
(Fig. 4).
Relationship between CDw75 expression and ST6Gal I 
activity from the same CRC patient and tissue
The Spearman's correlation coefficient test was carried out
in order to correlate both variables, CDw75 expression
and ST6Gal I activity from the same patient. The test indi-
cated no correlation (Rho Spearman = 0.106, p = 0.505),
although in many cases (75%) the two variables showed
a similar tissue pattern, such as high-activity and positive
expression for the CDw75 in tumour tissue from the same
patient.
Discussion
It can be assumed, that alterations of cell surface sugars
change the antigen recognition map of the cells. This fact
impacts on interaction patterns among them, as is the case
during cell differentiation. Furthermore, glycoconjugates
alterations during malignant transformation lead to cell-
Table 1: Relationship between CRC clinicopathologic features and ST6Gal I activity
ST6Gal Activity
Tumor p Tumor/Healthy p Net increase p n
Means ± SEM Means ± SEM Means ± SEM
Age (years)
< 69 61.89 ± 13.17 0.887 2.21 ± 0.52 0.981 54.52 ± 12.25 0.042 9
69-77 58.85 ± 15.18 4.25 ± 1.99 62.25 ± 21.74 9
> 77 38.48 ± 6.75 2.60 ± 0.89 20.23 ± 6.04 10
Tumour location
Proximal 41.36 ± 9.28 0.231 2.21 ± 0.87 0.442 28.09 ± 10.11 0.308 7
Distal 72.12 ± 12.58 3.54 ± 1.35 63.46 ± 14.78 13
Rectum 34.56 ± 8.03 2.01 ± 0.69 25.99 ± 9.26 7
Size (cm)
<4 69.89 ± 18.74 0.130 4.96 ± 2.28 0.033 56.86 ± 20.75 0.727 9
4-5 41.45 ± 9.07 1.49 ± 0.320 37.00 ± 13.83 9
> 5 55.81 ± 8.42 3.60 ± 1.17 38.47 ± 6.35 9
Histologic type
Poorly differentiated 8.27 0.208 1.49 0.371 2.72 0.156 1
Moderately differentiated 57.66 ± 7.63 3.27 ± 0.80 49.01 ± 8.99 24
Well differentiated 25.34 ± 0.98 0.80 ± 0.28 2.16 1
Growth type
Polypoid 47.28 ± 10.13 0.915 1.83 ± 0.39 0.414 36.93 ± 11.41 0.716 12
Non polypoid 34.31 ± 11.21 2.75 ± 1.16 23.24 ± 11.56 4
TNM classification
T
T1/T2 76.09 ± 30.13 0.223 3.68 ± 2.25 0.510 74.94 ± 38.60 0.421 3
T3 54.12 ± 8.08 3.12 ± 0.87 43.97 ± 9.65 33
T4 29.00 ± 9.49 1.33 ± 0.58 22.63 ± 19.91 4
N
N0 59.90 ± 10.26 0.139 3.27 ± 1.08 0.443 47.34 ± 11.58 0.491 24
N1 55.83 ± 14.00 3.53 ± 1.50 51.26 ± 16.17 9
N2 27.19 ± 6.90 1.26 ± 0.33 18.07 ± 12.27 7
M
M0 55.76 ± 7.60 0.616 3.16 ± 0.79 0.254 46.42 ± 8.92 - 37
M1 24.93 0.62 - 1
AJCC classification
I 76.09 ± 30.13 0.146 3.68 ± 2.25 0.597 74.94 ± 38.60 0.407 3
IIa 60.05 ± 11.39 3.30 ± 1.27 46.63 ± 12.82 20
IIb 13.17 ± 4.90 0.89 ± 0.59 2.72 2
IIIb 59.70 ± 15.26 3.89 ± 1.66 51.26 ± 16.17 8
IIIc 28.72 ± 7.96 1.42 ± 0.34 18.07 ± 12.27 6
IV - 0.62 - 1
Relationship between CRC patient's clinicopathologic features and tumour stading and ST6Gal I activity. Tumour/Healthy represents the quotient 
of the enzyme activity from the two tissues of the same patient. Net increase represents the difference of the enzyme activity from tumour and 
healthy tissues from the same patient. The ST6Gal I activity and the net increase are expressed as μU/mg protein. Data are represented as means ± 
SEM (standard error of the means) of the n patients analyzed. p was obtained from the Mann-Whitney U test (for tumour growth type) and 
Kruskall-Wallis test (for the rest of variables).BMC Cancer 2009, 9:431 http://www.biomedcentral.com/1471-2407/9/431
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cell contacts for tissue colonization or the issuance of
metastases [24]. Additionally, sialic acid enhancement in
the cell surface has been related with a more aggressive
behaviour of tumours and an increased metastatic poten-
tial [25]. Therefore, depending on the stage of tumour
evolution, different disruption levels of glycosyltrans-
ferase activities will be responsible for glycoconjugate
changes.
The present study detected significant differences between
ST6Gal I levels of activity in CRC tumour tissue and the
healthy control one. Likewise, it seems that malignant
transformation appears in parallel to an upward trend of
ST6Gal I activity, since transitional tissue activity values
are intermediate between those of healthy and tumour
ones. Mostafapour & Goldstein [26] reported that tumour
cells with high metastatic potential tend to file a high
ST6Gal I activity. Previous studies from our group [23]
detected differences between enzyme activity of healthy
tissue and transitional ones, in a reduced population of
patients. If this difference is confirmed in subsequent
analyses, it might seem that tissue cells suffer transitional
changes of enzyme activity, perhaps as a prior episode for
tumour processing. The current study is one of the few
which includes data from transitional tissue, and little is
known on this subject so far. Some alterations in transi-
tional tissue have been described regarding its healthy
counterpart: sialomucins increase or hyperdevelopment
and AG elongation, among others, suggesting that secre-
tor activity is stimulated [27,28]. Despite the foregoing, it
is unclear whether the neoplastic process leads to changes
in the adjacent tumour mucosa or it is the other way
around. So, further and larger studies are needed to clarify
the role of α(2,6)-sialylation on CRC origin. In this sense,
the assessment of the ST6Gal I activity in premalignant
lesions such as colorectal polyps may be useful to eluci-
date the link between ST6Gal I and CRC development.
Nevertheless, the analysis of ST6Gal I activity in colorectal
adenomas was not possible because the small size of the
resected polyps.
Table 2: Comparisons of ST6Gal I activity between clinicopathological features
Dun Test
Clinicopathological features Tumour Tumour/
Healthy
Net increase
Age (years)
<69 vs > 77
n.s. n.s. 7.78
Histologic type:
Moderately differentiated vs Well differentiated
2.53 6.59 8.24
T (T1/T2 vs T3) 4.0 n.s. 1.9
T (T1/T2 vs T4) 11 3.6 5.0
N (N0 vs N2) 7.0 3.0 5.6
AJCC (I vs IIIb) 6.0 2.8 4.9
AJCC (I vs IIIc) 5.8 2.6 4.5
AJCC (IIa vs IIIb) 7.0 5.2 6.4
AJCC (IIa vs IIIc) 6.9 4.8 5.9
AJCC (IIa vs IV) 4.4 n.s. n.s.
AJCC (IIb vs IIIb) 5.4 1.8 3.6
AJCC (IIb vs IIIc) 5.3 1.6 3.3
AJCC (IIb vs IV) 3.5 n.s. n.s.
T (T1/T2 vs T3) 4.0 n.s. 1.9
Comparisons of ST6Gal I activity between clinicopathological features by Dun test. The data represent the value of Dun test, which are indicative of 
the degree of correlation between the variables. Tumour/Healthy: quotient of the enzyme activity from the two tissues of the same patient. Net 
increase: difference of the enzyme activity from tumour and healthy tissues from the same patient. n.s.: not significant.
Percentage of colorectal adenomas and healthy, transitional  and tumour CRC specimens which showed positive CDw75  expression in the immunohistochemical study Figure 2
Percentage of colorectal adenomas and healthy, 
transitional and tumour CRC specimens which 
showed positive CDw75 expression in the immuno-
histochemical study.BMC Cancer 2009, 9:431 http://www.biomedcentral.com/1471-2407/9/431
Page 7 of 10
(page number not for citation purposes)
The present study observed that ST6Gal I activity showed
a minor increase in the oldest patients, therefore indicat-
ing that the enhancement of ST6Gal I is one of the signals
of worse prognosis in the CRC. Its largest increase is
recorded in the youngest patients, who are likely to
develop more devastating tumours. There is therefore a
need for a larger population study, in order to clarify the
ST6Gal I activity decrease with CRC progression as well as
to verify whether the emergence of the disease at advanced
ages determines the lower activity.
In as far as tumour size is concerned, as the primary focus
grows, the ST6Gal I activity decreases, and therefore the
enzyme function would seem most related to training,
deployment and initial growth of the tumour through sia-
lylation of the membrane oligosaccharides, than to subse-
quent tumour growth. On the contrary, we have also
noticed that the enzyme activity is higher in such moder-
ately differentiated tumours compared with well differen-
tiated ones.
Upon taking tumour stage into account, we observed that
ST6Gal I activity decreased proportionally as the malig-
nancy tumour degree increases. We highlight the presence
of statistically significant differences in decline of ST6Gal
I activity as it progresses through the infiltration degree or
lymph node involvement. The higher ST6Gal I activity in
the initial stages is consistent with results from a recent
study [29] that reports the changes induced by the expres-
sion of ST6Gal I in CRC cell lines that were originally
deprived of the same. In this sense, the ST6Gal I activity
has been related with the establishment of more partner-
ships between extracellular substrates recognized by
integrins, as well as with an accumulation and differential
distribution of β-integrins in the membrane. This study
once again demonstrates the role of ST6Gal I in intercellu-
lar relationships, and between cells and matrix. Moreover,
Immunohistochemical expression of CDw75 Figure 3
Immunohistochemical expression of CDw75. A) Section from colorectal adenomas showing CDw75 expression. B) Sec-
tion from healthy colon mucosa showing negative CDw75 immunoreactivity. C) Section from CDw75 positive tumour colon 
mucosa, evidenced by the presence of a brown precipitate. Scale bar = 25 μm.BMC Cancer 2009, 9:431 http://www.biomedcentral.com/1471-2407/9/431
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Seales et al. [15], described that an increased α(2,6)-sia-
lylation of β1-integrins in CRC tissues, is more likely to
alter interactions of tumour cells with their local matrix
environment. Forced ST6Gal I expression in SW48 cells
led to increased β1-mediated attachment and migration
on collagen I and increased coupling of the β1-subunit to
the cytoskeleton-associated protein talin. The manner in
which altered the sialylation regulates β1-integrin func-
tion is not well understood; however, sialylation could
directly affect the ligand-binding activity of collagen
receptors [13].
Another focus of attention in our study was the CDw75
expression in CRC. Results showed that the CDw75 anti-
gen [siaα(2,6)Galβ(1,4)GlcNAc], sialylated by ST6Gal I, is
expressed in a high percentage of tumour CRC specimens.
It is noteworthy that in the case of healthy tissue, 100% of
specimens did not show expression for CDw75, and the
transitional tissue expression was although significant
compared to the no expression in healthy specimens. In
this sense, this work is groundbreaking because to date,
there are no studies that involve transitional tissue to ana-
lyze antigen CDw75 expression. Since the transitional tis-
sue from our study (without histological appearance of
malignancy) presents a ST6Gal I activity that is greater
than its healthy counterpart, it seems logical to think that
sialylation is enhanced and, consequently, that the syn-
thesis of CDw75 antigen, and the probability of detection,
are higher. The immunohistochemical and kinetic data
included in this study indicate that in the transitional tis-
sue ST6Gal I is indeed expressed, resulting in a significant
percentage of cases with positive expression for the
CDw75 antigen.
On the other hand, with the aim to elucidate if CDw75 is
implicated in the development of CRC, we studied this
antigen expression in colorectal adenomas, the precursor
lesions of CRC. We found expression of CDw75 in 20% of
colorectal adenomas analyzed. The presence of α(2,6)-
linked sialic acid residues in colorectal adenomas detected
by SNA lectin have been reported by Sata et al. [30], and
this expression was associated with malignant transforma-
tion of adenomas. In our study we have not found corre-
lation between CDw75 expression in adenomas and their
malignant potential. It must be considered that the specif-
icity of SNA lectin differs from that of the antibody anti-
CDw75, since the first one recognizes both
NeuAα(2,6)Gal (CDw75 antigen) and NeuAcα(2,6)Gal-
NAc (STn antigen) sequences [31].
To our knowledge, there is only one previous survey in
colon adenocarcinoma, which shows that the CDw75 is
not expressed in healthy mucosa but it is expressed in
51.8% of tumour tissues [19]. Moreover, in gastric carci-
noma the CDw75 showed similar percentages to those of
CRC, 48.4% [17] or 51.4% [18], where the healthy one in
both cases was negative. Therefore, these authors have
proposed the CDw75 antigen as a molecular marker of
gastric carcinoma. Our data showing a very high expres-
sion in CRC reinforces the potential role of CDw75 anti-
gen as a marker for malignant transformation.
In the current study, the percentage of CRC specimens
found to be positive for CDw75 was higher in tumour
CRC advanced stages. Therefore, an increased expression
of CDw75 was associated with malignancy or lymphatic
invasion, despite the fact that statistical significance was
not reached. Elpek et al. [19] likewise described highest
antigen expression in cases with deeper penetration or
advanced tumour stages, as well as in those with metas-
tases. On the other hand, results in literature for gastric
adenocarcinoma, have also associated the percentage of
CDw75 positive specimens with the tumour stage, the
existence of metastasis and the involvement of lymph
nodes [17,18]. A lower overall patients survival rate asso-
ciated with positive expression of antigen has also been
described [17,18]. An increase in the expression of
CDw75 in tumours with a deeper penetration could be a
reflection of increased ST6Gal I activity, especially in
tumours with moderate and well differentiated morphol-
ogy [19]. In fact, positive expression of CDw75 in tumour
tissues and absence in healthy ones could indicate that
ST6Gal I is increased in CRC. On the other hand, with
regards to the tumour infiltration, enzyme activity
decreases while the expression of antigen increases. It's
very complicated to find correlation between ST6Gal I
activity and CDw75 expression. In this sense, Dall'Olio et
al. have well documented the lack of correlation between
the ST6Gal I activity and expression on CRC [32], as well
as the non-direct correspondence between the ST6Gal I
catalytic potential and the degree of colon glycoprotein
α(2,6)-sialylation [33]. The results herein reported also
Percentage of positive and negative CDw75 expression in  AJCC stages Figure 4
Percentage of positive and negative CDw75 expres-
sion in AJCC stages. n = number of specimens.BMC Cancer 2009, 9:431 http://www.biomedcentral.com/1471-2407/9/431
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failed in the search for a correlation between the catalytic
activity of the ST6Gal I enzyme and the expression of the
α(2,6)-sialylated CDw75 determinant. In this sense, it is
kwon the existence of multiple ST6Gal I transcripts that
account for the post-transcriptional modulation of the
enzyme in colon cancer [33,34]. So, it's likely that com-
plex post-transcriptional mechanisms of ST6Gal I have
effects on CDw75 expression, and may be the reason of
that we haven't found correlation between both variables.
Finally, another possible explanation for this result is that
the antigen could be sialylated by another sialyltrans-
ferase, apart from the ST6Gal I.
We might assume that a greater increase in ST6Gal I activ-
ity leads to a higher CDw75 expression. In this sense, it
must be pointed out that both variables showed a similar
pattern in 75% of CRC specimens.
Conclusion
In conclusion, this work demonstrates that ST6Gal I activ-
ity and CDw75 expression are enhanced in CRC. Likewise,
many of tumours studied showed a high ST6Gal I activity
and positive expression for the CDw75. Our observations
suggest that the two variables may play a role in tumour
progression. The expression of CDw75 in colorectal ade-
nomas suggests that this antigen may be a tumour marker
in colorectal carcinomas, as proposed in the case of gastric
carcinomas.
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